Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T-cell therapy in a subset of B-cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene-modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.

中文翻译：

---

开启绿灯，进行嵌合抗原受体T细胞治疗。

涉及通过嵌合抗原受体（CAR）转基因对T细胞进行基因修饰的过继细胞疗法为扩大这种方法有效治疗癌症的有效性提供了一种有前途的策略。尽管在CAR T细胞治疗后，在B细胞恶性肿瘤的一部分中观察到了显着的抗肿瘤反应，但在实体癌的情况下，这一点尚未得到扩展。在临床前模型中已经测试了许多有希望的策略，包括对肿瘤微环境进行重新编程，提高基因修饰的T细胞的特异性和安全性以及利用内源性免疫反应，这些策略可能对实体癌患者产生重大影响。